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well informed before receiving treat-
ment. The HCTC employs a team of
counsellors who are all HIV positive,
the majority of whom are on ART.
Starting a patient on ART should be an
intensive process, but one that should
bring the satisfaction of treatment suc-
cess.
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Malaria morbidity and mortality is ris-
ing, principally as a result of increas-
ing antimalarial resistance.1 Resistance
means that there is a shift to the right
in the dose-response (concentration-
effect) relationship. Plasmodium falci-
parum has developed clinically signifi-
cant resistance to all classes of anti-
malarial drugs, with the possible
exception of artemisinin derivatives.2
Resistance is thought to arise from
spontaneous chromosomal point muta-
tions or gene duplications, which are
independent of the drug selection pres-
sure. Once formed, these more resist-
ant parasites have a survival advan-
tage in the presence of antimalarial
drugs. This is determined by the intrin-
sic frequency with which these point
mutations occur and the degree of
resistance conferred by the change. 
Several factors encourage the spread
of resistance. These include:
• The proportion of transmissible
malaria infections exposed to sub-
therapeutic concentrations of an
antimalarial.
• The drug concentration profile (a
long elimination phase favours
resistance), the pattern of drug use
and the level of immunity in the
community. 
Antimalarial resistance results in pro-
longed illness, hospitalisation and
death as well as a vicious circle of an
increase in treatment failure, leading
to increased gametocyte carriage and
thus increased malaria transmission,
particularly of resistant parasites, fur-
ther increasing drug pressure and anti-
malarial drug resistance.
In the 1960s resistance to chloroquine
developed almost simultaneously in
South-East Asia and South America,
and has spread remorselessly so that
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Fig. 1. Antimalarial drug efficacy on the north-western border of Thailand.7 The
decline of antimalarial efficacy of chloroquine (CQ), sulfadoxine-pyrimethamine
(SP), mefloquine 15 mg/kg then 25 mg/kg (M15, M25), and quinine (Q) is con-
trasted with the very slow decline in the efficacy of quinine-tetracycline (QT) and
the sustained efficacy of artesunate plus mefloquine (AM).
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chloroquine is ineffective in most
malaria-endemic areas, including
South Africa.3 Many countries in east
and southern Africa then replaced
chloroquine with the antifolate, sulfa-
doxine-pyrimethamine (SP), as first-line
treatment for uncomplicated malaria.
KwaZulu-Natal introduced SP in 1988,
while Mpumalanga and Limpopo
changed policy only in 1997.
Resistance to SP develops more rapid-
ly than to chloroquine, and by 2000
SP in vivo cure rates at 42 days were
only 12% in KwaZulu-Natal.4 This nec-
cessitated an urgent change in treat-
ment policy. In contrast, SP cure rates
have remained above 90% in
Mpumalanga and Limpopo, where SP
was introduced 9 years later than in
KwaZulu-Natal.6
South East Asia (particularly along the
Thai-Burmese and Thai-Cambodian
borders), has historically developed
antimalarial resistance most rapidly,
and events there demonstrate the neg-
ative consequences of serial monother-
apy (Fig. 1). South Africa has a simi-
lar intensity and distribution of malaria
transmission, and comparable drug
regulation to Thailand. In both coun-
tries the low intensity of malaria trans-
mission results in few patients develop-
ing any protective immunity; conse-
quently almost all infections are symp-
tomatic and result in patients seeking
treatment. The reasonable public
health care infrastructure results in
most malaria infections being treated
with an antimalarial, thus increasing
drug pressure and the spread of anti-
malarial resistance.
The emergence of resistance can be
prevented by the use of combinations
of antimalarials with different mecha-
nisms of action and therefore different
targets. For many years the same
rationale has been applied in the
treatment of tuberculosis, HIV infec-
tions and many cancers. Artemisinin
derivatives have particular advantages
for use in combination therapy, as
they result in the most rapid reduction
in parasite load. This is significant, as
the selection for resistant mutants is
dependent on parasite load.
Artemisinin derivatives are also the
only first-line malaria treatments to act
on gametocytes (the stage of the
malaria parasite’s life cycle responsi-
ble for ongoing malaria transmission),
thereby potentially reducing malaria
transmission and particularly the trans-
mission of resistant strains of malaria.
There is growing international consen-
sus that wide-scale systematic imple-
mentation of artemisinin-based combi-
nation therapy (ACT) is one of few
effective measures that will enable
malaria-endemic countries to achieve
the ambitious goals set in Abuja to
‘roll back malaria’, particularly the
halving of malaria morbidity and mor-
tality by 2010.8 The introduction of
ACT (artesunate plus mefloquine) in
north-west Thailand in 1994 has led to
a remarkable decrease in malaria
transmission and a reversal of the
resistance trend, despite the estab-
lished resistance to mefloquine
monotherapy. By 2000 this regimen
was still almost 100% effective.9 A
dramatic decline in malaria mortality
observed in Vietnam has been associ-
ated with the deployment of ACT.7
Improved cure rates and decreased
gametocyte carriage have been con-
firmed in limited African field trials.10
In response to the SP-resistant malaria
epidemic in KwaZulu-Natal that
peaked in 2000, artemether-lume-
fantrine was implemented as first-line
treatment in January 2001.5 This,
together with concurrent improvements
in vector management, resulted in
marked decreases in notified malaria
cases (Fig. 2) and malaria-related hos-
pital admissions and deaths. In the
western border area of Thailand, a
47% reduction in the incidence of P.
falciparum infections was observed in
the 12 months after the introduction of
artesunate plus mefloquine.11 This fur-
ther improved to a six-fold reduction
over a 10-year period.9 The similar
experience of marked public health
benefits in western Thailand suggests
that the decrease in malaria morbidity
in KwaZulu-Natal reflects the benefits
of ACT, rather than being specific to
artemether-lumefantrine. 
Artemether-lumefantrine is adminis-
tered as a 6-dose (3-day) regimen,
and needs to be taken with fat-contain-
ing food or drink. Although achievable
with adequate patient education,
adherence with both these require-
ments is challenging, as symptom
relief often occurs after 3 doses, and
those with malaria may not be able to
access or tolerate foods containing fat.
This provided motivation for the imple-
mentation of the simpler and cheaper
regimen of artesunate plus SP in the
public sector in Mpumalanga (where
SP remains effective enough for use in
Fig. 2. Number of notified malaria cases in KwaZulu-Natal, South Africa, by month
in relation to timing of significant malaria control interventions.
A. Reintroduction of DDT for indoor residual spraying (IRS) of traditional structures in KwaZulu-Natal in March 2000. 
B. Introduction of indoor residual spraying (IRS) in southern Mozambique in October 2000. 
C. Implementation of artemether-lumefantrine (AL) for the treatment of uncomplicated falciparum malaria in KZN in
January 2001.
Source: KwaZulu-Natal Department of Health, South Africa
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an ACT), under Section 21 approval
of the Medicines Control Council. A
marked decrease in malaria case noti-
fications has followed this introduction
of ACT (Mpumalanga Department of
Health Notification data — not
shown).
It should be noted that these beneficial
effects on antimalarial resistance and
transmission depend on ensuring that
the majority of falciparum infections
are treated with artemisinin-based
combinations, and that the use of
either component alone is curtailed.
This is facilitated by the use of fixed-
dose ACT (e.g. artemether–lume-
fantrine), strict drug regulation and
adequate patient education. Patients
who receive inadequate treatment
(either because of poor adherence,
vomiting of oral treatment, underdos-
ing or poor drug quality, etc.) are an
especially important source of drug
resistance. Delaying the spread of
resistance therefore requires correct
prescribing of adequate doses of
appropriately selected antimalarials
and patient education to ensure full
adherence to prescribed drug regi-
mens. The widespread use of ACT in
the treatment of uncomplicated malar-
ia has played an important role in
malaria control in South Africa.
Quinine (preferably in combination
with doxycycline or clindamycin), how-
ever, remains the preferred treatment
in patients with more severe malaria,
in pregnant women, and children
under 1 year of age with uncomplicat-
ed malaria.
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